Patrizia Borsotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10193647/publications.pdf

Version: 2024-02-01

26 papers	2,314 citations	331259 21 h-index	610482 24 g-index
26 all docs	26 docs citations	26 times ranked	3374 citing authors

#	Article	IF	Citations
1	Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial Cells. American Journal of Pathology, 2002, 160, 673-680.	1.9	502
2	Endothelin-1 Induces an Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. American Journal of Pathology, 2000, 157, 1703-1711.	1.9	322
3	Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. Journal of the National Cancer Institute, 1995, 87, 293-298.	3.0	220
4	Bioavailability of VEGF in Tumor-Shed Vesicles Depends on Vesicle Burst Induced by Acidic pH. Neoplasia, 2006, 8, 96-103.	2.3	168
5	Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. Clinical Cancer Research, 2004, 10, 4813-4821.	3.2	144
6	Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia, 2003, 17, 52-59.	3.3	142
7	Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Research, 2003, 63, 1534-7.	0.4	94
8	Antiangiogenic activity of aplidine, a new agent of marine origin. British Journal of Cancer, 2004, 90, 2418-2424.	2.9	82
9	Vascular Disrupting Activity of Tubulin-Binding 1,5-Diaryl-1H-imidazoles. Journal of Medicinal Chemistry, 2009, 52, 7906-7910.	2.9	65
10	The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clinical Cancer Research, 2006, 12, 1839-1849.	3.2	54
11	p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene, 2001, 20, 7293-7300.	2.6	51
12	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	2.3	50
13	Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clinical Cancer Research, 2002, 8, 1182-8.	3.2	50
14	Thrombospondinâ€1 is part of a Slugâ€independent motility and metastatic program in cutaneous melanoma, in association with <scp>VEGFR</scp>â€1 and <scp>FGF</scp>â€2. Pigment Cell and Melanoma Research, 2015, 28, 73-81.	1.5	45
15	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
16	Posttranscriptional Stimulation of Endothelial Cell Matrix Metalloproteinases 2 and 1 by Endothelioma Cells. Experimental Cell Research, 2000, 258, 384-394.	1.2	43
17	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer Chemotherapy and Pharmacology, 2013, 72, 879-887.	1.1	37
18	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis, 2019, 22, 133-144.	3.7	37

#	Article	IF	Citations
19	Inhibition of matrix metalloproteinases by overâ€expression of tissue inhibitor of metalloproteinaseâ€2 inhibits the growth of experimental hemangiomas. International Journal of Cancer, 2001, 91, 241-247.	2.3	29
20	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	2.3	28
21	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	1.3	28
22	Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. Clinical Cancer Research, 2005, 11, 2720-2726.	3.2	23
23	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells, 2020, 9, 952.	1.8	23
24	Effect of alltrans-retinoic acid (ATRA) on the adhesive and motility properties of acute promyelocytic leukemia cells. , 1997, 70, 72-77.		21
25	Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts. Connective Tissue Research, 2015, 56, 355-363.	1.1	10
26	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	1.5	2